Oral administration of myricetin one time a day for the period of 84 days in adenomatous polyposis coli multiple intestinal neoplasia (APCMin/+) mice showed a reduction in degree of dysplasia and number of dysplastic cells in each polyp, induction of apoptosis and inhibition of proliferation of cancer cells, modulation of Wnt/β‐catenin and GSK‐3β pathways, reduction of IL‐6 and PGE2 (pro‐inflammatory cytokines) in blood, and downregulation of the p38 MAPK/Akt/mTOR pathways (Li et al., 2016). The gene discussed is AKT1; the disease is cancer.